Exelixis Inc (EXEL) Stock Price
EXELStock
$62.23+58.71%52W
Market Cap$15.42B
P/E19.70x
PEG Ratio2.56
Div yield—
Beta0.44
EXEL Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)25.79%
Price vs S&P 500 (4W)10.08%
PEG Ratio2.56
VGM Score68.19
P/E Ratio (Annual)19.70x
EXEL Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.86 | $0.91 | +5.20%(+$0.05) | |
| Q1 2026 | $0.76 | $0.87 | +14.02%(+$0.11) | |
| Q4 2025 | $0.81 | $0.94 | +16.17%(+$0.13) | |
| Q3 2025 | $0.67 | $0.78 | +16.24%(+$0.11) | |
| Q2 2025 | $0.65 | $0.75 | +16.24%(+$0.10) |
EXEL Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.77
3.68
3.65
3.56
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
| TECHBio-Techne Corp. | D | C | B | 9.4x | -0.4% | 66.2% | 6.0% | $72.57 |
About Exelixis Inc
Exelixis Inc is a biopharmaceutical company that discovers and commercializes oncology treatments. Its portfolio includes Cabometyx for renal cell and hepatocellular carcinoma, Cometriq for metastatic medullary thyroid cancer, and Cotellic (in partnership with Roche) for melanoma.